These results suggest that the PI3K, MAPK, and NF-kappa B pathways are all involved in the regulation of PD-L1 in EGFR-T790M mutation-mediated EGFR-TKI resistant NSCLC cells. Here, EGFR is linked to non-small cell lung carcinoma.